Thrombolytic Science To Present At Elsevier, Inc. Business Intelligence's Therapeutic Area Partnership Conference In Boston
CAMBRIDGE, Mass., Nov. 18, 2015 /PRNewswire/ -- Thrombolytic Science, LLC (TSI) announced today that Alexis C. Wallace, President & Chief Executive Officer, will be presenting TSI's lead thrombolytic TS01 on November 19, 2015 at 4:30 PM at the Elsevier Business Intelligence's Therapeutics Area Partnership conference in Boston as part of the Cardiovascular/Metabolic Diseases track.
TSI's clot buster treatment represents a novel approach to thrombolysis for the treatment of acute ischemic stroke and other thrombotic diseases. Two thrombolytics, including the proprietary compound TS01, are used sequentially resulting in a synergistic therapeutic effect achieved at much lower and therefore safer doses than the ones used in standard monotherapy today. The treatment is designed to combine greater thrombolytic efficacy with improved safety.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers."
"We are very pleased that Thrombolytic Science and TS01 have been selected as one of the top 10 partnering opportunities in the cardiovascular arena," said TSI President & CEO Alexis C. Wallace. "Augmenting treatment options based on well known mechanisms of action, using a simple intravenous regimen that is both effective, safer, and could be made available much earlier to a wider population will likely have a substantial beneficial impact on acute stroke care."
Each year, strokes affect 15 million people worldwide and, with 6.7 million deaths, stroke is the second leading cause of death in the world. In the United States, stroke is the leading cause of long-term disability in adults and the fifth leading cause of death, costing the US healthcare system in excess of $73 billion each year. Approximately 80 percent of all strokes are caused by blood clots.
About Thrombolytic Science, LLC
Thrombolytic Science, LLC is a privately-held vascular medicine and biotechnology company based in Cambridge, MA, currently developing a new-generation clot-dissolving therapy with the first novel mechanism of action in 20 years for stroke and other thrombotic diseases. TSI's technology is based upon pioneering work by its co-founders on the well-understood and clinically tested natural thrombolytic, prourokinase.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thrombolytic-science-to-present-at-elsevier-business-intelligences-therapeutic-area-partnership-conference-in-boston-300181045.html
SOURCE Thrombolytic Science, LLC